checkAd

    Guerbet  165  0 Kommentare NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.

    NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics

    -- Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies, production, and commercialization with Nuclidium’s in depth know-how of the copper radioisotope production and theranostic development --

    Basel, Switzerland and Villepinte, France, May 22, 2024NUCLIDIUM and Guerbet (GBT) today announced a strategic partnership to advance NUCLIDIUM’s diagnostic and therapeutic copper-based radiopharmaceuticals. This partnership will provide NUCLIDIUM access to Guerbet’s knowledge and extensive network in diagnostic imaging, manufacturing, and clinical trials, aiding the progression of NUCLIDIUM’s theranostic candidates towards commercialization. Guerbet has made a strategic, non-exclusive investment in NUCLIDIUM as part of the agreement. As part of the agreement, François Nicolas, Senior Vice President of R&D at Guerbet, will join NUCLIDIUM’s Board of Directors as an observer. No further details of the agreement have been disclosed.

    “Guerbet is a global leading expert in diagnostic imaging with a longstanding record in developing, manufacturing, and globally distributing medical imaging solutions. This collaboration emphasizes the value of our innovative copper-based theranostic pipeline, which aims to provide cancer patients with comprehensive solutions from the precise diagnosis to effective treatments. Our goal is to accelerate the clinical development of our unique product candidates and we look forward to gaining valuable strategic insights from François and the Guerbet team,” said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM.

    François Nicolas, Senior Vice President of R&D Guerbet added: “NUCLIDIUM leads in pioneering a new generation of targeted radiotheranostics that could vastly extend patient benefits. Targeted radiopharmaceuticals represent a significant advancement in cancer treatment, yet face supply limitations and production challenges. NUCLIDIUM’s copper-based strategy presents a promising approach to address these issues, enhancing patient access and improving disease staging and treatment. This aligns with Guerbet's growth strategy to broaden our core business areas. I am excited to support Leila and her team in demonstrating the clinical value of its platform.”

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Guerbet NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics. NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics - Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies, production, and …